NCT05432492View on ClinicalTrials.gov

A Study of AK112 in Patients With Unresectable Hepatocellular Carcinoma (HCC)

PHASE2UnknownINTERVENTIONAL

Enrollment

60

Participants

Timeline

Start Date

August 31, 2022

Primary Completion Date

August 31, 2023

Study Completion Date

August 31, 2024

Conditions

Hepatocellular Carcinoma

Interventions

DRUG

AK112

IV infusion, specified dose on specified days

Sponsors

Lead Sponsor

All Listed Sponsors

lead

Akeso

INDUSTRY